Frequency of procedural and medical treatments of actinic keratosis

Ranpariya, Varun; Muddasani, Suraj; Mahon, Andrew B.; Feldman, Steven R.

doi:10.1016/j.jaad.2021.03.047

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Despite an overall low concern when diagnosed with AK, most participants believed that treatment was important. There are multiple treatment options for AKs, including both surgical and field-directed treatments, and cryosurgery and 5-FU are the most commonly prescribed therapies [ 2 , 12 ]. While cryosurgery is intended to treat isolated or a few lesions, topical treatments, such as 5-FU, are more efficacious to treat both clinical and subclinical AKs [ 2 , 12 , 13 ].…”

Section: Discussionmentioning

confidence: 99%

“…There are multiple treatment options for AKs, including both surgical and field-directed treatments, and cryosurgery and 5-FU are the most commonly prescribed therapies [ 2 , 12 ]. While cryosurgery is intended to treat isolated or a few lesions, topical treatments, such as 5-FU, are more efficacious to treat both clinical and subclinical AKs [ 2 , 12 , 13 ]. However, 5-FU is associated with frequent LSRs, and patients with a greater number of AKs at baseline may be predisposed to severe LSRs [ 14 , 15 ].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis

Singh¹,

McCain²,

Grada³

et al. 2023

JMIR Dermatol

View full text Add to dashboard Cite

Background Actinic keratosis (AK) is a common premalignant skin lesion, and topical 5-fluorouracil (5-FU) is commonly used in field-directed therapy. However, 5-FU is associated with frequent local skin reactions. Objective This study aimed to qualitatively assess experiences among patients with AK who refuse retreatment with 5-FU. Methods Semistructured interviews were conducted with 10 adult participants who had received treatment with 5-FU for AK between January 1, 2017, and January 1, 2020, and refused future treatment with 5-FU. Results were analyzed using qualitative research methods. Results Although most participants had low concern upon having received a diagnosis of AK, most felt that treatment is very important. When initiating treatment with 5-FU, most cited recommendation by their health care professionals as the primary motivator and initially had low concern regarding treatment. The side effects associated with treatment were physically and psychosocially burdensome for most participants and led to temporary lifestyle adjustments. After treatment, most did not believe that their health care provider prepared them for treatment or were unsure. While half of the participants felt that 5-FU helped treat AKs, half were either unsure, due to premature discontinuation, or did not think that 5-FU treated their AKs. Conclusions 5-FU is one of the most commonly prescribed treatments for AKs, yet most patients experienced both a physical and psychosocial burden with the treatment. Inability to assess efficacy due to premature discontinuation secondary to 5-FU–related reactions is common, and shared decision-making, navigating treatment options, and taking into account patient preferences may be critical to help assure better adherence and outcomes. Although our study was limited by input from participants who refused future treatment with 5-FU, most stated that they would still continue to seek treatment for AKs in the future and would consider other topical treatments, especially if associated with a milder tolerability profile.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis

Singh¹,

McCain²,

Grada³

et al. 2023

JMIR Dermatol

View full text Add to dashboard Cite

show abstract

“…Unfortunately, in the United States, dermatologists underutilize AK field therapies and rely on lesion targeted, cryotherapy for the treatment of AKs. Investigators captured 2603 US National Ambulatory Medical Care Survey visits for AKs between 2009 and 2016, representing an estimated 57.9 million AK visits, found that 50.8% of all AK visits used cryotherapy, and only 1.34% used 5‐fluoruracil (5‐FU), 1.38% imiquimod, and 0.377% ingenol mebutate 9 …”

Section: Treatment Of Aksmentioning

confidence: 99%

“…Fifteen high-risk solid organ transplant recipients (SOTRs), with a history of more than or equal to two new NMSCs in previous (5-FU), 1.38% imiquimod, and 0.377% ingenol mebutate. 9 How does freezing an AK result in AK cell death? Freezing skin results in ice crystals to develop between the cells causing an osmotic gradient, drawing water out from the AK cells.…”

Section: Chemoprevention Of Aksmentioning

confidence: 99%

Actinic keratoses: The latest in therapy

Berman

2021

Dermatological Reviews

View full text Add to dashboard Cite

The following is a review of the pathogenesis and natural history of actinic keratoses, their progression to squamous cell carcinoma, and recent findings and insights into the mechanisms of action of chemopreventative and field therapeutic agents for actinic keratoses are highlighted. Oral nicotinamide appears to be a safe and tolerable chemopreventative agent although its effectiveness requires continued use. Tirbanibulin ointment 1% is novel in its proposed mechanism of action and requires the shortest period of treatment of currently US Food and Drug Administration-approved, topically applied field therapies for actinic keratoses.

show abstract

Patients who refuse topical 5-fluoruoracil treatment: a qualitative analysis. (Preprint)

Singh¹,

McCain²,

Grada³

et al. 2022

Preprint

View full text Add to dashboard Cite

BACKGROUND Actinic keratosis (AK) is a common premalignant skin lesion and topical 5-fluorouracil (5-FU) is commonly used field-directed therapy. However, 5-FU is associated with frequent local skin reactions. OBJECTIVE To qualitatively assess experience in those who refuse treatment with 5-FU. METHODS Semi-structured interviews were conducted in 10 adult participants who had received treatment with 5-FU for AK between 1/1/2017 and 1/1/2020 and refused future treatment with 5-FU. Results were analyzed using qualitative research methods. RESULTS Although most participants had low concern when receiving a diagnosis of AK, most felt treatment was very important. When initiating treatment with 5-FU, most cited the recommendation by their healthcare professional as the primary motivator and initially had low concern with treatment. Most participants experienced difficulty with the physical burden of treatment, which caused lifestyle adjustments and a negative psychosocial impact. After treatment, most did not believe their HCP prepared them for treatment or were unsure. While half the participants felt 5-FU helped treat AKs, half were either unsure, due to premature discontinuation, or did not think 5-FU treated their AKs. CONCLUSIONS 5-FU is one of the most commonly prescribed treatments for AKs. Although participants considered treatment important, most considered the side effects of 5-FU were not worth the benefits, and most experienced both a physical and psychosocial burden secondary to treatment. Moreover, participants were either unsure or were not adequately prepared for treatment. Although our study was limited by input from participants who refused future treatment with 5-FU, most stated they would still continue to seek treatment for AKs in the future, and would consider other topical treatments, especially if associated with a milder AE profile. Non-adherence to treatment is a major cause of resistant disease and is a major hurdle in the treatment of skin conditions. Inability to assess efficacy due to premature discontinuation secondary to 5-FU related AEs was a common theme in our cohort. Counseling patients on the benefits and risks of a medication, in addition to therapeutic alternatives, may increase adherence and improve outcomes.

show abstract

Frequency of procedural and medical treatments of actinic keratosis

Cited by 4 publications

References 3 publications

Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis

Refusal of Retreatment With Topical 5-Fluorouracil Among Patients With Actinic Keratosis: Qualitative Analysis

Actinic keratoses: The latest in therapy

Patients who refuse topical 5-fluoruoracil treatment: a qualitative analysis. (Preprint)

Contact Info

Product

Resources

About